2,992
回編集
差分
ナビゲーションに移動
検索に移動
→New vaccine development
}}
*A systematic review found incidences of YF across African countries were '''quite heterogenous (I<sup>2</sup>=99.4%) ''' as per 100,000 population ranging from '''<1 in Nigeria''' to '''10,350 in Ghana''' and failed in quantitative synthesis for meta-analysis.
{{quote
|content=Nwaiwu, A. U., Musekiwa, A., Tamuzi, J. L., Sambala, E. Z., & Nyasulu, P. S. (2021). The incidence and mortality of yellow fever in Africa: a systematic review and meta-analysis. BMC Infectious Diseases, 21(1), 1–11. https://doi.org/10.1186/s12879-021-06728-x
}}
*A systematic review and meta-analysis concluded from which synthesized 14 articles concluded that '''case fatality rate of YF among severe disease''' is '''39%''' (95%CI 31-47).
{{quote
|content=Servadio, J. L., Muñoz-Zanzi, C., & Convertino, M. (2021). Estimating case fatality risk of severe Yellow Fever cases: systematic literature review and meta-analysis. BMC Infectious Diseases, 21(1), 1–12. https://doi.org/10.1186/s12879-021-06535-4
===Effectiveness (real world research)===
===Effectiveness of fractional dose in emergency campaigns===
===Correlates of protection===
*Neutralization titer ≥1:10
*Log<sub>10</sub> neutralization index (LNI) ≥0.7
===Severe side effects===
===YF vaccine and Pregnancy===
*Though YF vaccine is generally contraindicated for pregnant women because of theoretical risk for fetus, multiple reports have accordingly proved safety in babies born from mothers accidentally immunized by YF vaccine.
{{quote
|content=Thomas, R. E., Lorenzetti, D. L., Spragins, W., Jackson, D., & Williamson, T. (2012). The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: Systematic review. American Journal of Tropical Medicine and Hygiene, 86(2), 359–372. https://doi.org/10.4269/ajtmh.2012.11-0525
}}
===YF vaccine and Breast feeding===
===YF vaccine and Multiple sclerosis===
*In a ''prospective'' self-controlled case series study published in 2011 reported that '''between 1 and 5 weeks after YF immunization''' ('at risk period') MS patients experienced '''higher exacerbation rate''' compared to other periods ('''rate ratio 12.778'''; '''8.57 episodes per year''' at risk period vs '''0.67 episodes per year''' at non-risk period).
{{quote
|content=Farez, M. F., & Correale, J. (2011). Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Archives of Neurology, 68(10), 1267–1271. https://doi.org/10.1001/archneurol.2011.131
}}
*Whereas another ''retrospective'' self-controlled cohort published in 2020 reported that '''during 3 months after YF immunization''' ('exposure risk period') MS patients '''did not experienced significant increase of disease exacerbation''' associated with YF immunization.
{{quote
|content=Huttner, A., Eperon, G., Lascano, A. M., Roth, S., Schwob, J. M., Siegrist, C. A., & Lalive, P. H. (2020). Risk of MS relapse after yellow fever vaccination: A self-controlled case series. Neurology(R) Neuroimmunology & Neuroinflammation, 7(4), 1–6. https://doi.org/10.1212/NXI.0000000000000726
}}
===YF vaccine and Egg allergy===
===New vaccine development===
*'''Inactivated YF vaccine ''' has been under development. '''Phase 1 ''' trial of '''XRX-001''' purified whole-virus, β-propiolactone-'''inactivated vaccine ''' (cultured in Vero cell, adjuvanted with alumninum hydroxide) investigated 2 separated doses in 21 days apart with antigen of 4.8 μg, 0.48 μg and placebo.
{{quote
|content=Monath, T. P., Fowler, E., Johnson, C. T., Balser, J., Morin, M. J., Sisti, M., & Trent, D. W. (2011). An Inactivated Cell-Culture Vaccine against Yellow Fever. New England Journal of Medicine, 364(14), 1326–1333. https://doi.org/10.1056/NEJMoa1009303
}}
*'''Non-replicating viral vector YF vaccine''' has been under development. '''Phase 1''' trial of '''YF protein-producing Modified Vaccinia Ankara-Bavarian Nordic virus''' has been completed but has not been reported in peer-reviewed journals.
{{quote
|content=NCT02743455 - A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers. https://classic.clinicaltrials.gov/ct2/show/NCT02743455
}}
*'''mRNA YF vaccine''' is under development in '''mice and macaque models'''.
{{quote
|content=Medina-Magües, L. G., Mühe, J., Jasny, E., Medina-Magües, E. S., Roth, N., Lopera-Madrid, J., Salas-Quinchucua, C., Knuese, C., Petsch, B., & Osorio, J. E. (2023). Immunogenicity and protective activity of mRNA vaccine candidates against yellow fever virus in animal models. Npj Vaccines, 8(1). https://doi.org/10.1038/s41541-023-00629-7
}}
